MedTrace Logo

Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease

NCT04482179 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-09-15

Study results available
· View outcomes & findings →

Summary

Impaired verbal communication is a cardinal symptom of Alzheimer Disease (AD) and the source of enormous distress and disability. Effective therapies for this deficit are lacking. In light of the emerging literature demonstrating that Transcranial Magnetic Stimulation (TMS) improves general cognition in subjects with Alzheimer Disease (AD), the investigators propose to study the effectiveness of TMS as a therapy for impaired verbal communication. The hypothesis to be tested is that TMS combined with Constraint Induced Language Therapy (CILT) improves verbal communication more than sham TMS and CILT. A second aim is to use state-of-the-art neuroimaging to understand the mechanisms underlying any beneficial effect of the treatment.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

Active TMS

Active TMS will be delivered at 100% motor threshold

BEHAVIORAL

CILT

60-90 minutes of CILT will be administered during each treatment session

DEVICE

Sham TMS

Sham TMS will be administered

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • H. Branch Coslett, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482179 on ClinicalTrials.gov